Poor Glycemic Control in People with T1D and T2D—Results from the International Diabetes Management Practices Study (IDMPS)
Authors: ASCHNER PABLO , GAGLIARDINO JUAN J. , ILKOVA HASAN M. , LAVALLE-GONZALEZ FERNANDO J. , RAMACHANDRAN AMBADY , KADDAHA GHAIDA , MBANYA JEAN CLAUDE , SHESTAKOVA MARINA V. , CHANTELOT JEAN-MARC , CHAN JULIANA C. 
Published: June 2018

The IDMPS is a global observational survey on the management and patterns of care of people with type 1 (T1D) and type 2 (T2D) diabetes in the developing world. We report glycemic control in 2016-17 of people in 24 countries across Africa, the Middle East, South Asia, and Eurasia.

In people with T1D, HbA1c levels targeted by physicians were &lt;7% in 45.3% and 7-7.5% in 44.6% of people. Taking an HbA1c level of &lt;7% as indicative of good control, overall, glycemic control was poor, with this target was achieved by only 21.8% and 30.1% of participants with T1D and T2D, respectively. The majority of people had a glucometer; however, use was insufficient as indicated by the limited number of daily glucose measurements. In addition, fewer than half of people with T2D on insulin self-adjusted their dose.

These data show that overall, few people in the developing world are achieving glycemic control, and that the proportion of people with HbA1c &lt;7.0% is considerably lower than reported rates in the U.S.A. The lack of self-monitoring of blood glucose and of self-adjustment of insulin calls for improved patient education regarding use of glucometers and titration of insulin.

Disclosure

P. Aschner: Other Relationship; Self; Sanofi. J.J. Gagliardino: Other Relationship; Self; Sanofi. H.M. Ilkova: Advisory Panel; Self; Abbott, Eli Lilly and Company, Novartis AG, Novo Nordisk A/S, Boehringer Ingelheim GmbH, Servier, Merck Sharp & Dohme Corp.. Speaker's Bureau; Self; AstraZeneca. Advisory Panel; Self; Medtronic, Roche Diabetes Care Health and Digital Solutions, Bilim İlac. F.J. Lavalle-Gonzalez: Advisory Panel; Self; Sanofi. Speaker's Bureau; Self; Sanofi. Research Support; Self; Janssen Pharmaceuticals, Inc.. Advisory Panel; Self; Janssen Pharmaceuticals, Inc.. Speaker's Bureau; Self; Janssen Pharmaceuticals, Inc.. Consultant; Self; Novo Nordisk Inc.. Advisory Panel; Self; AstraZeneca. Speaker's Bureau; Self; AstraZeneca. Research Support; Self; AstraZeneca. Advisory Panel; Self; Merck Sharp & Dohme Corp.. Research Support; Self; Boehringer Ingelheim Pharmaceuticals, Inc.. Advisory Panel; Self; Boehringer Ingelheim Pharmaceuticals, Inc.. Speaker's Bureau; Self; Boehringer Ingelheim Pharmaceuticals, Inc.. Advisory Panel; Self; Eli Lilly and Company. Speaker's Bureau; Self; Eli Lilly and Company. Advisory Panel; Self; Abbott. Speaker's Bureau; Self; Abbott. A. Ramachandran: None. G. Kaddaha: Other Relationship; Self; Sanofi. J. Mbanya: Advisory Panel; Self; GlaxoSmithKline plc.. Speaker's Bureau; Self; Novo Nordisk A/S, Sanofi, Servier. M.V. Shestakova: None. J. Chantelot: Employee; Self; Sanofi. Stock/Shareholder; Self; Sanofi. J.C. Chan: Consultant; Self; Bayer AG. Other Relationship; Self; Bayer AG. Consultant; Self; Sanofi. Other Relationship; Self; Sanofi, Eli Lilly and Company, Amgen Inc.. Consultant; Self; AstraZeneca, Merck & Co., Inc., Pfizer Inc.. Other Relationship; Self; Pfizer Inc.. Board Member; Self; Asia Diabetes Foundation. Stock/Shareholder; Self; GemVCare. Other Relationship; Self; Merck Sharp #x0026 Dohme Corp.. Consultant; Self; Boehringer Ingelheim Pharmaceuticals, Inc., Novartis AG, Eli Lilly and Company.